Electrical impedance myography (EIM), a painless, noninvasive test that sends a small electrical current through a muscle, may help doctors…
Articles by Margarida Maia, PhD
Treatment with Nexviazyme (avalglucosidase alfa), a next-generation enzyme replacement therapy from Sanofi, may help babies with infantile-onset…
Heart problems in late-onset Pompe disease appear milder and less specific than in the disease’s infantile-onset form, a review…
While most adults on Myozyme (alglucosidase alfa) for late-onset Pompe disease develop antibodies to the replacement enzyme, these usually…
A baby boy with infantile-onset Pompe disease and a severely enlarged heart was treated early with Nexviazyme (avalglucosidase…
Switching from Lumizyme (alglucosidase alfa) to the newer treatment Nexviazyme (avalglucosidase alfa) improved muscle strength and eased airway…
Long-term use of Myozyme (alglucosidase alfa), marketed as Lumizyme in the U.S., helped individuals with late-onset Pompe disease…
A man was diagnosed with late-onset Pompe disease (LOPD) after prenatal genetic counseling, even though he exhibited no symptoms.
A test that measures walking speed over 10 meters (33 feet) offers a simpler and less demanding alternative to the…
Many adults with late-onset Pompe disease (LOPD) see their own health status as declining over time, with difficulty swallowing…